Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suviton is a dietary supplement developed by Omnifarma Kiev, specifically formulated to support joint and cartilage health. It typically contains a combination of glucosamine sulfate and chondroitin sulfate, which are essential components of the cartilage matrix. These ingredients work synergistically to stimulate the synthesis of proteoglycans and hyaluronic acid, inhibit enzymes that degrade cartilage (such as matrix metalloproteinases), and improve the lubrication and elasticity of joints. It is indicated for individuals with joint disorders, such as osteoarthritis, or those seeking to maintain joint mobility and prevent age-related cartilage wear. The product is positioned as a source of structural components for connective tissue repair and maintenance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suviton.